News

Currently, the company is enrolling a Phase 1 trial analysing ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with MCC. MCC is a rare but aggressive form of

Under the deal terms, the company will provide funding for clinical development of its next-generation antibody-drug conjugate (ADC), NAV-001. The experimental ADC targets and kills tumour cells which

The double-blind, multicentre, placebo-controlled, randomised, dose-finding Phase II OCEAN(a)-DOSE study was designed for evaluating olpasiran’s tolerability, safety, as well as the optimal dose in atherosclerotic cardiovascular disease (ASCVD)

The new 1,500m2 facility will expand the company’s large-scale viral vectors production capabilities for vaccines and gene therapy. It has been designed to meet the increasing demand for

Brukinsa has been approved to treat relapsed/refractory (R/R) MZL adult patients who have previously received at least one anti-CD20-based therapy. The Bruton’s tyrosine kinase (BTK) small molecule inhibitor,

Under the deal terms, the company obtained an exclusive option for evaluating the regulatory, clinical development and commercialisation plan for CWRU’s intellectual property portfolio for up to 12

Under the collaboration, the company will be responsible for the vaccine epitope selection portion using its in silico vaccine design toolkit, iVAX. EpiVax will work as a subgrantee

Characterised by recurrent inflammation of the skin associated with intense pruritus, AD is a non-contagious chronic, inflammatory disease of the skin. Almirall has submitted the application based on

Under the collaboration, AmbioPharm will help Ariceum in manufacturing and supplying cGMP peptide conjugates. The peptide conjugates will be radio-labelled as the radiopharmaceutical end-product and will be used